How Arthur was paid
$734,450 in total for 2024, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Options | Other | Total |
|---|---|---|---|---|
| David J. Arthurformer President and Chief Executive Officer | $176,153 | $8,265 | $550,032 | $734,450 |
| Mark J. RosenblumExecutive Vice President, Finance and Chief Financial Officer | $330,000 | $11,372 | $9,050 | $350,422 |
What changed and why
- $734KDavid J. Arthur received a total compensation of $734,450 in 2024, reflecting his transition to a consulting role and a $500,000 severance payment.
- $350KMark J. Rosenblum earned a total compensation of $350,422 in 2024, with a base salary remaining steady at $330,000.
- Neither named executive officer received a cash bonus or salary raise for the 2024 fiscal year.
- Stock options were granted to align executive performance with stockholder interests.
Other Decoy Therapeutics proxy statements
- 2026 proxy statement
Frederick E. Pierce paid $225,036.
Filed Jun 04, 2026
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.